Biotechnology company Pluri has announced the issuance of a patent by the US Patent and Trademark Office (USPTO) for its ...

T-cell activation involves two phases, enabling a more precise immune response. This insight may boost cancer immunotherapy effectiveness. A research team led by Wolfgang Kastenmüller and Georg ...

Pluri (PLUR) announced that the U.S. Patent and Trademark Office, USPTO, has issued a patent covering the Company’s immune cell expansion ...

Nigel McCracken, chief operating officer, Virax Biolabs, discusses the expansion of its ViraxImmune platform into areas such as transplant monitoring, vaccine efficacy, latent virus reactivation, and ...

To treat glioblastoma, Purdue researchers are developing antibody-based immunotherapies to improve the recruitment and ...

The key is a natural immune protein called CD40L ... CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL ...

The granted patents titled "System and Methods For Immune Cells Expansion and Activation In Large Scale” focus on a system and method for culturing and/or activating immune cells in a large scale, ...

The granted patents titled“System and Methods For Immune Cells Expansion and Activation In Large Scale” focus on a system and method for culturing and/or activating immune cells in a large ...